Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees.  Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.

Eli Lilly & Co. terlibat dalam penemuan, pengembangan, serta produksi dan penjualan produk farmasi. Perusahaan ini berkantor pusat di Indianapolis, Indiana dan saat ini mempekerjakan 47.000 karyawan penuh waktu. Produk kesehatan kardiometaboliknya termasuk Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, dan lainnya; Humulin, Humulin 70/30, dan lainnya; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, dan VERVE-301. Produk onkologinya termasuk Cyramza, Erbitux, Tyvyt, dan Verzenio. Produk imunnya termasuk Ebglyss, Olumiant, Omvoh, dan Taltz. Produk neurosciencenya termasuk Emgality dan Kisunla. Perusahaan ini juga terlibat dalam upaya penemuan, pengembangan, dan produksi radiofarmasi, serta terapi radioligan klinis dan pra-klinis yang sedang dikembangkan untuk pengobatan kanker. Perusahaan ini juga sedang mengembangkan inhibitor kecil molekul oral dari integrin a4b7 untuk penyakit radang usus (IBD). Perusahaan ini sedang mengevaluasi kandidat terapi gen novelnya, ixoberogene soroparvovec.

Eli Lilly

JPMorgan

Exxon Mobil

Johnson & Johnson

SPDR S&P500 ETF

Costco

Netflix

General Electric

Vanguard Total Stock Market ETF

Coca-Cola

Toyota

AstraZeneca

Linde PLC

Invesco QQQ Trust

QUALCOMM

Banco Santander

Danaher

Sony

Unilever

Deere

Lockheed Martin

British American Tobacco

Sanofi

Vertex Pharmaceuticals

Robinhood

Bristol-Myers Squibb

Mercadolibre

Vanguard Dev Markets ETF

CVS Health

Vanguard Value ETF

Nike

Carvana

Vanguard Total Bond Market ETF

Scotiabank

Marsh & McLennan

Northrop Grumman

Nu Holdings

Apollo Global Management

Cadence Design

General Motors

Equinix

Vanguard DivApp ETF

FedEx

Vanguard Emerging Markets ETF

Schlumberger

Western Digital

iShares Russell 2000 ETF

Seagate Technology

Canadian National Railway

Colgate-Palmolive

iShares 20+ Year Treasury ETF

American Electric Power

AFLAC

Vanguard Total Intl Bond ETF

EOG Resources

Vanguard High Dividend ETF

Vanguard Info Tech ETF

Alnylam Pharmaceuticals

Baidu

Dominion Energy

MicroStrategy

Take-Two Interactive

MSCI

Diamondback Energy

Financial Select Sector SPDR

Block, Inc.

eBay

Prudential Financial (US)

Kroger

Prudential (UK)

Health Care Select Sector SPDR

Occidental Petroleum

Cognizant

Energy Select Sector SPDR

ASE Technology Holding

Keysight Technologies

Expedia

ArcelorMittal

Vanguard Real Estate ETF

Otis Worldwide

SPDR Dow Jones ETF

AST SpaceMobile

Raymond James

iShares MBS ETF

iShares iBoxx Corp Bond ETF

iShares 7-10 Year Treasury ETF

Nutrien

First Solar

Affirm

Tapestry

Futu Holdings

General Mills

Ralph Lauren

iShares MSCI ACWI ETF

NetApp

Vanguard Short-Term TIPS ETF

Quest Diagnostics

Xpeng

Saham Eli Lilly

Tentang Eli Lilly

Statistik Kunci